# CF Bankshares Inc.: Form 10-Q for the period ended Mar 31, 2024

- Company: [CF Bankshares Inc.](/companies/cfbk.md) (CIK 1070680)
- Form: 10-Q
- Filed: 2024-05-14
- Accepted by EDGAR: May 14, 2024, 14:16 ET
- Period: 2024-03-31
- Accession: 0001070680-24-000017
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1070680/000107068024000017/cfbk-20240331x10q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1070680/000107068024000017/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2024-03-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Interest expense | 3 months, 2024-01-01 to 2024-03-31 | $17.8m | us-gaap:InterestExpense |
| Income tax | 3 months, 2024-01-01 to 2024-03-31 | $695.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2024-01-01 to 2024-03-31 | $3.1m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2024-01-01 to 2024-03-31 | $0.47 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2024-01-01 to 2024-03-31 | $0.48 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2024-01-01 to 2024-03-31 | 6,478,177 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months, 2024-01-01 to 2024-03-31 | −$1.2m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months, 2024-01-01 to 2024-03-31 | $3.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 3 months, 2024-01-01 to 2024-03-31 | $386.0k | us-gaap:PaymentsOfDividendsCommonStock |
| Cash and equivalents | at 2024-03-31 | $236.9m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Total assets | at 2024-03-31 | $2.04bn | us-gaap:Assets |
| Total liabilities | at 2024-03-31 | $1.88bn | us-gaap:Liabilities |
| Shareholders' equity | at 2024-03-31 | $158.0m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 1,599 characters.

(a) None.

(b) Not applicable.

(c) The following table provides information concerning purchases of the Holding Company’s shares of common stock made by or on behalf of the Company or any “affiliated purchaser” as defined in Rule 10b-18(a)(3) under the Securities Exchange Act of 1934, as amended, during the three months ended March 31, 2024.

| Period | Total number of common shares purchased |  | Average price paid per common share | Total number of common shares purchased as part of publicly announced plans or programs (3) | Maximum number of common shares that may yet be purchased under the plans or programs |
| --- | ---: | ---: | ---: | ---: | ---: |
| January 1, 2024 through January 31, 2024 | 6,247 | (1) | 20.61 | 5,050 | 235,447 |
| February 1, 2024 through February 29, 2024 | 5,265 | (2) | 21.28 | 800 | 234,647 |
| March 1, 2024 through March 31, 2024 | 3,000 |  | 20.03 | 3,000 | 231,647 |
| Total | 14,512 |  | $20.73 | 8,850 |  |

(1) Includes 1,197 shares of common stock surrendered to the Company for the payment of taxes upon the vesting of restricted stock and 5,050 shares of common stock repurchased under the stock repurchase program.

(2) Includes 4,465 shares of common stock surrendered to the Company for the payment of taxes upon the vesting of restricted stock and 800 shares of common stock repurchased under the stock repurchase program.

(3) On July 5, 2023, the Company’s Board of Directors authorized a new stock repurchase program pursuant to which the Company may repurchase up to 250,000 shares of the Company’s common stock on or before June 30, 2024.

## Risk factors

As filed, 459 characters.

There are certain risks and uncertainties in our business that could cause our actual results to differ materially from those anticipated. A detailed discussion of our risk factors is included in “Item 1A. Risk Factors” of Part I of the Company’s Annual Report on Form 10-K for the year ended December 31, 2023. There were no material changes to those risk factors as presented in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023.

Filed May 14, 2024.
Source: SEC EDGAR, the filing index for accession 0001070680-24-000017. Last ingested by Listed: Nov 13, 2026, 01:50 ET. No prices; not investment advice.
